Long-term clinical outcome in STEMI patients treated with primary PCI and drug-eluting or bare-metal stents: insights from a high-volume single-center registry

TY - JOUR

T1 - Long-term clinical outcome in STEMI patients treated with primary PCI and drug-eluting or bare-metal stents: insights from a high-volume single-center registry

AU - Pedersen, Sune

AU - Galatius, Soren

AU - Mogelvang, Rasmus

AU - Abildstrom, Steen Z

AU - Sorensen, Rikke

AU - Galloe, Anders

AU - Abildgaard, Ulrik

AU - Hansen, Peter

AU - Davidsen, Ulla

AU - Iversen, Allan

AU - Bech, Jan

AU - Madsen, Jan K

AU - Jensen, Jan S

PY - 2011/8

Y1 - 2011/8

N2 - Objective: Use of drug-eluting stents (DES) in patients with ST-elevation myocardial infarction (STEMI) during routine primary percutaneous coronary intervention (pPCI) is controversial. Methods: From January 2004 to July 2008, a total of 2,155 STEMI patients were treated with pPCI [DES or bare-metal stent (BMS)] at a single high-volume invasive center. We present 4-year outcomes in this observational registry study. Results: A total of 1,725 were treated with DES and 430 with BMS. Patients treated with DES were younger and had more complex angiographic characteristics compared to BMS patients. Patients treated with DES had lower adjusted risk of target lesion revascularization (TLR) [hazard ratio (HR) ≤ 0.68; 95 confidence interval (CI): 0.40-0.98; p ≤ 0.04], but had a trend toward increased risk of definite stent thrombosis (HR ≤ 1.96; 95 CI: 0.83-4.61; p ≤ 0.12). No difference was found when evaluating all-cause mortality and non-fatal myocardial infarction. Conclusions: In this study, we set out to evaluate the independent impact of DES or BMS treatment on long-term clinical outcomes in STEMI patients treated with pPCI in a real-life setting. DES use was associated with a reduced risk of TLR, but a trend toward increased risk of stent thrombosis was found. However, this safety issue did not translate into an increased risk of death or overall non-fatal myocardial infarction for DES patients.

AB - Objective: Use of drug-eluting stents (DES) in patients with ST-elevation myocardial infarction (STEMI) during routine primary percutaneous coronary intervention (pPCI) is controversial. Methods: From January 2004 to July 2008, a total of 2,155 STEMI patients were treated with pPCI [DES or bare-metal stent (BMS)] at a single high-volume invasive center. We present 4-year outcomes in this observational registry study. Results: A total of 1,725 were treated with DES and 430 with BMS. Patients treated with DES were younger and had more complex angiographic characteristics compared to BMS patients. Patients treated with DES had lower adjusted risk of target lesion revascularization (TLR) [hazard ratio (HR) ≤ 0.68; 95 confidence interval (CI): 0.40-0.98; p ≤ 0.04], but had a trend toward increased risk of definite stent thrombosis (HR ≤ 1.96; 95 CI: 0.83-4.61; p ≤ 0.12). No difference was found when evaluating all-cause mortality and non-fatal myocardial infarction. Conclusions: In this study, we set out to evaluate the independent impact of DES or BMS treatment on long-term clinical outcomes in STEMI patients treated with pPCI in a real-life setting. DES use was associated with a reduced risk of TLR, but a trend toward increased risk of stent thrombosis was found. However, this safety issue did not translate into an increased risk of death or overall non-fatal myocardial infarction for DES patients.

M3 - Journal article

SN - 1042-3931

VL - 23

SP - 328

EP - 333

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

IS - 8

ER -